CFH and complement 3 glomerulopathy: Two patients treated with eculizumab in the recent therapeutic trial also had heterozygous mutations affecting Cfh and MCP. 50Unlike homozygous Cfh deficiency, for which an animal model exists (discussed later), the functional basis of heterozygous mutations in C3 glomerulopathy remains unclear, notwithstanding that some have shown a correlation with AP dysregulation in patients with aHUS.